Adjuvant androgen deprivation therapy for poor-risk, androgen receptor–positive salivary duct carcinoma

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

Emmanuel S. Antonarakis, Changxue Lu, Hao Wang et al. · New England Journal of Medicine · 2014 · 2.7K citations · Full text

Medicine, Oncology, Pharmacology +17

Pathology Databanking and Biobanking in The Netherlands, a Central Role for PALGA, the Nationwide Histopathology and Cytopathology Data Network and Archive

M. K. Casparie, A.T.M.G. Tiebosch, Gary T. Burger et al. · Analytical Cellular Pathology · 2007 · 884 citations · Full text

Medicine, Biomedical Informatics, Pathology +11

IL-23 secreted by myeloid cells drives castration-resistant prostate cancer

Arianna Calcinotto, Clarissa Spataro, Elena Zagato et al. · Nature · 2018 · 388 citations

Medicine, Immunology, Oncology +14

Clinical and immunohistologic typing of salivary duct carcinoma

M Jaehne, Kerstin Roeser, Thorsten Jaekel et al. · Cancer · 2005 · 318 citations · Full text

Medicine, Oncology, Oral Pathology +17

Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer

Chengfei Liu, Wei Lou, Yezi Zhu et al. · Cancer Research · 2015 · 242 citations · Full text

Medicine, Oncology, Pharmacology +17